<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981123</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-NHR-SER-2009/1</org_study_id>
    <nct_id>NCT00981123</nct_id>
  </id_info>
  <brief_title>Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia</brief_title>
  <official_title>Non-interventional Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, non-comparative, epidemiological study to collect and analyse real life data
      on schizophrenic patients receiving quetiapine according to the standard medical practice in
      Croatia. The main objectives are to assess after 6 months of quetiapine therapy severity of
      illness and global improvement in patients using Clinical Global Impression (CGI) scale.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess severity of illness and global improvement in patients after 6 months of quetiapine therapy using Clinical Global Impression (CGI) scale</measure>
    <time_frame>CGI - 2 measures (after 3 and after 6 months of quetiapine therapy)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure therapeutic response in schizophrenic patients using BPRS scale</measure>
    <time_frame>BPRS - 2 measures (after 3 and after 6 months of quetiapine therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate compliance with the prescribed antipsychotic treatment</measure>
    <time_frame>CGI - 2 measures (after 3 and after 6 months of quetiapine therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate prescribing practices for quetiapine in the treatment of schizophrenia in Croatia</measure>
    <time_frame>3 measures (at the time of quetiapine therapy introduction, after 3 and 6 m of quetiapine therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate type and frequency of concomitant therapy</measure>
    <time_frame>At visit 1 ( day 0) and visit 2 (day 90) recorded all changes in concomitant therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate average number of hospitalisations</measure>
    <time_frame>At visit 1 ( day 0) and visit 2 (day 90) recorded all changes in numbers of hospitalisations</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate frequency of mental illnesses in patient's family</measure>
    <time_frame>at visit 1 (day 0)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients or hospitalised patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of schizophrenia

          -  Patients who are already treated with quetiapine for at least 12 weeks (outpatients or
             hospitalised patients)

          -  Patients capable of signing ICF

        Exclusion Criteria:

          -  Patients with hypersensitivity to active substance or any of the excipients of this
             product

          -  Patients with contraindication for quetiapine therapy according to the approved SmPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Marija Gjurovic, MD , MSc</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Medical Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreja Hasenohrl, DVM</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Medical Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bjelovar</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cakovec</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dubrovnik</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Popovaca</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pula</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sibenik</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sisak</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slavonski brod</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varazdin</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinkovci</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vukovar</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zabok</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zadar</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>January 7, 2011</last_update_submitted>
  <last_update_submitted_qc>January 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>MC MD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

